Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CBLB502 × Gastrointestinal × Clear all
NCT02715882 2017-02-09

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

BioLab 612 LLC

Phase 2 Unknown
40 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡